About Us

GeneCentric’s mission is to address the urgent unmet need in precision oncology for better biomarkers and to bring these biomarkers to blood testing. Through AI and the inherent multimodal output of our GenomicsNext™ platform, we are accelerating advancements in cancer genomics.

Building on over a decade of expertise with gene expression, we developed ExpressCT™, a breakthrough technology that measures gene expression using information embedded in circulating tumor DNA (ctDNA), to provide a more complete liquid biopsy solution for precision medicine.

We deploy this technology through GenomicsNext, an integrated platform for comprehensive liquid biopsy testing. The platform is a simple, elegant solution that simultaneously provides high-fidelity DNA variants and gene expression.

By delivering the valuable dimension of gene expression to liquid biopsies, GenomicsNext is the best-in-class enabler of liquid biopsy technologies, discoveries and applications. This technology meets the genomic testing field where it is today to expand the reach and utility of ctDNA sequencing beyond alterations. We are actively leveraging our platform through strategic collaborations with diagnostics, pharmaceutical and biotechnology companies.

Michael V. Milburn, PhD

Chief Executive Officer and President




Kirk_Beebe

Kirk Beebe, PhD

Chief Scientific Officer




Chenyqua Shepard, CPA

Chief Operating Officer




Myla Lai-Goldman, MD

Founder & Chair

Arnold J. Levine, PhD

Director

Michael V. Milburn, PhD

Chief Executive Officer and President

Charles M. Perou, PhD

Founder and Director

Clay B. Thorp

General Partner, Hatteras Venture Partners

N. Hayes

David Neil Hayes, MD MPH MS

Observer and Founder

Prasanth Reddy, MD, MPH, FACP

Director

Don M. Hardison

Director